{
"info": {
"nct_id": "NCT03193060",
"official_title": "A Multi-centre, Prospective, Observational Study on Effectiveness and Safety of ZOLADEX® (Goserelin Acetate Implant) 10.8 mg and ZOLADEX® (Goserelin Acetate Implant) 3.6 mg in Chinese Patients With Localized or Locally Advanced Hormonal Treatment -naïve Prostate Cancer",
"inclusion_criteria": "1. Ability to provide informed consent, complete all study assessments and have complete medical record;\n2. Male aged 18 years and over;\n3. Diagnosis of localized or locally advanced prostate cancer requiring immediate hormonal therapy;\n4. Being prescribed Zoladex ® (goserelin acetate implant) 10.8 mg or Zoladex ® (goserelin acetate implant) 3.6 mg in accordance with the terms of marketing authorization as monotherapy or in combination with androgen blockade (CAB);\n5. More than 26 weeks' life expectancy;\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
"exclusion_criteria": "1. Patients who are planned to receive radiation therapy;\n2. Patients with hypersensitivity to LHRH, its analogues, or any components of goserelin depot;\n3. Previous or concurrent hormonal therapy including surgical castration, androgen blockers, oestrogen therapy, or other LHRH agonists.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "1. Ability to provide informed consent, complete all study assessments and have complete medical record;",
"criterions": [
{
"exact_snippets": "Ability to provide informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
}
]
},
{
"exact_snippets": "complete all study assessments",
"criterion": "study assessments",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
}
]
},
{
"exact_snippets": "have complete medical record",
"criterion": "medical record",
"requirements": [
{
"requirement_type": "completeness",
"expected_value": true
}
]
}
]
},
{
"line": "2. Male aged 18 years and over;",
"criterions": [
{
"exact_snippets": "Male",
"criterion": "gender",
"requirements": [
{
"requirement_type": "value",
"expected_value": "male"
}
]
},
{
"exact_snippets": "aged 18 years and over",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "3. Diagnosis of localized or locally advanced prostate cancer requiring immediate hormonal therapy;",
"criterions": [
{
"exact_snippets": "Diagnosis of localized or locally advanced prostate cancer",
"criterion": "prostate cancer",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"localized",
"locally advanced"
]
}
]
},
{
"exact_snippets": "requiring immediate hormonal therapy",
"criterion": "hormonal therapy",
"requirements": [
{
"requirement_type": "necessity",
"expected_value": "immediate"
}
]
}
]
},
{
"line": "4. Being prescribed Zoladex ® (goserelin acetate implant) 10.8 mg or Zoladex ® (goserelin acetate implant) 3.6 mg in accordance with the terms of marketing authorization as monotherapy or in combination with androgen blockade (CAB);",
"criterions": [
{
"exact_snippets": "Being prescribed Zoladex ® (goserelin acetate implant) 10.8 mg or Zoladex ® (goserelin acetate implant) 3.6 mg",
"criterion": "Zoladex prescription",
"requirements": [
{
"requirement_type": "dosage",
"expected_value": [
"10.8 mg",
"3.6 mg"
]
}
]
},
{
"exact_snippets": "in accordance with the terms of marketing authorization",
"criterion": "marketing authorization compliance",
"requirements": [
{
"requirement_type": "compliance",
"expected_value": true
}
]
},
{
"exact_snippets": "as monotherapy or in combination with androgen blockade (CAB)",
"criterion": "therapy type",
"requirements": [
{
"requirement_type": "type",
"expected_value": [
"monotherapy",
"combination with androgen blockade (CAB)"
]
}
]
}
]
},
{
"line": "5. More than 26 weeks' life expectancy;",
"criterions": [
{
"exact_snippets": "More than 26 weeks' life expectancy",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">",
"value": 26,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be MALE",
"criterions": [
{
"exact_snippets": "MALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "male"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 100 Years",
"criterions": [
{
"exact_snippets": "maximum age of 100 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 100,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "1. Patients who are planned to receive radiation therapy;",
"criterions": [
{
"exact_snippets": "planned to receive radiation therapy",
"criterion": "radiation therapy",
"requirements": [
{
"requirement_type": "planned treatment",
"expected_value": true
}
]
}
]
},
{
"line": "2. Patients with hypersensitivity to LHRH, its analogues, or any components of goserelin depot;",
"criterions": [
{
"exact_snippets": "hypersensitivity to LHRH",
"criterion": "hypersensitivity to LHRH",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "hypersensitivity to ... its analogues",
"criterion": "hypersensitivity to LHRH analogues",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "hypersensitivity to ... any components of goserelin depot",
"criterion": "hypersensitivity to components of goserelin depot",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "3. Previous or concurrent hormonal therapy including surgical castration, androgen blockers, oestrogen therapy, or other LHRH agonists.",
"criterions": [
{
"exact_snippets": "Previous or concurrent hormonal therapy including surgical castration",
"criterion": "hormonal therapy",
"requirements": [
{
"requirement_type": "types",
"expected_value": [
"surgical castration"
]
}
]
},
{
"exact_snippets": "Previous or concurrent hormonal therapy including ... androgen blockers",
"criterion": "hormonal therapy",
"requirements": [
{
"requirement_type": "types",
"expected_value": [
"androgen blockers"
]
}
]
},
{
"exact_snippets": "Previous or concurrent hormonal therapy including ... oestrogen therapy",
"criterion": "hormonal therapy",
"requirements": [
{
"requirement_type": "types",
"expected_value": [
"oestrogen therapy"
]
}
]
},
{
"exact_snippets": "Previous or concurrent hormonal therapy including ... other LHRH agonists",
"criterion": "hormonal therapy",
"requirements": [
{
"requirement_type": "types",
"expected_value": [
"LHRH agonists"
]
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}